Cargando…

Commentary: Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial

Detalles Bibliográficos
Autores principales:	Leblhuber, Friedrich, Steiner, Kostja, Schuetz, Burkhard, Fuchs, Dietmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6624731/ https://www.ncbi.nlm.nih.gov/pubmed/31333558 http://dx.doi.org/10.3389/fneur.2019.00667

Ejemplares similares

Commentary: Effect of Probiotic Supplementation on Cognitive Function and Metabolic Status in Alzheimer's Disease: A Randomized, Double-Blind and Controlled Trial
por: Leblhuber, Friedrich, et al.
Publicado: (2018)

Probiotic Supplementation in Patients with Alzheimer’s Dementia - An Explorative Intervention Study
por: Leblhuber, Friedrich, et al.
Publicado: (2018)

The Immunopathogenesis of Alzheimer’s Disease Is Related to the Composition of Gut Microbiota
por: Leblhuber, Friedrich, et al.
Publicado: (2021)

Knock-on effect of periodontitis to the pathogenesis of Alzheimer’s disease?
por: Leblhuber, Friedrich, et al.
Publicado: (2020)

Correction to: Knock-on effect of periodontitis to the pathogenesis of Alzheimer’s disease?
por: Leblhuber, Friedrich, et al.
Publicado: (2020)

Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
por: Agahi, Azadeh, et al.
Publicado: (2018)

Corrigendum: Does Severity of Alzheimer's Disease Contribute to Its Responsiveness to Modifying Gut Microbiota? A Double Blind Clinical Trial
por: Agahi, Azadeh, et al.
Publicado: (2019)

Treatment of patients with geriatric depression with repetitive transcranial magnetic stimulation
por: Leblhuber, F., et al.
Publicado: (2019)

Repetitive Transcranial Magnetic Stimulation With H-Coil in Alzheimer's Disease: A Double-Blind, Placebo-Controlled Pilot Study
por: Leocani, Letizia, et al.
Publicado: (2021)

The role of the gut microbiota and fecal microbiota transplantation in neuroimmune diseases
por: Wu, Nan, et al.
Publicado: (2023)

Epilepsy, gut microbiota, and circadian rhythm
por: Wang, Yao, et al.
Publicado: (2023)

Antiviral therapy: Valacyclovir Treatment of Alzheimer’s Disease (VALAD) Trial: protocol for a randomised, double-blind, placebo-controlled, treatment trial
por: Devanand, D P, et al.
Publicado: (2020)

The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
por: Yang, Dongming, et al.
Publicado: (2019)

Creutzfeldt-Jakob Disease: Alterations of Gut Microbiota
por: Guo, Yanjun, et al.
Publicado: (2022)

Repetitive transcranial magnetic stimulation in the treatment of resistant depression: changes of specific neurotransmitter precursor amino acids
por: Leblhuber, F., et al.
Publicado: (2021)

Corrigendum: The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease
por: Yang, Dongming, et al.
Publicado: (2020)

Effect of Levodopa Initiation on the Gut Microbiota in Parkinson's Disease
por: Palacios, Natalia, et al.
Publicado: (2021)

Emerging role of gut microbiota dysbiosis in neuroinflammation and neurodegeneration
por: Solanki, Riddhi, et al.
Publicado: (2023)

A review of studies on gut microbiota and levodopa metabolism
por: Zhong, Zhe, et al.
Publicado: (2023)

Efficacy of probucol on cognitive function in Alzheimer’s disease: study protocol for a double-blind, placebo-controlled, randomised phase II trial (PIA study)
por: Lam, Virginie, et al.
Publicado: (2022)

Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial
por: Vivash, Lucy, et al.
Publicado: (2021)

Crosstalk Between the Gut Microbiota and the Brain: An Update on Neuroimaging Findings
por: Liu, Ping, et al.
Publicado: (2019)

Gut Microbiota and Targeted Biomarkers Analysis in Patients With Cognitive Impairment
por: Lu, Shourong, et al.
Publicado: (2022)

Role of Gut Microbiota in Multiple Sclerosis and Potential Therapeutic Implications
por: Wang, Xu, et al.
Publicado: (2022)

Altered gut microbiota and metabolites in untreated myasthenia gravis patients
por: Ding, Xiao-Jun, et al.
Publicado: (2023)

Expanding Representation of Low and Middle Income Countries in Global Dementia Research: Commentary From the Alzheimer's Association
por: Sexton, Claire, et al.
Publicado: (2021)

Modulation of the gut–brain axis via the gut microbiota: a new era in treatment of amyotrophic lateral sclerosis
por: Hong, Du, et al.
Publicado: (2023)

Gut Microbiota in Acute Ischemic Stroke: From Pathophysiology to Therapeutic Implications
por: Battaglini, Denise, et al.
Publicado: (2020)

The Role of Gut Microbiota in Neurodegenerative Diseases: Current Insights and Therapeutic Implications
por: Jain, Arpit, et al.
Publicado: (2023)

Ursodeoxycholic acid as a novel disease-modifying treatment for Parkinson’s disease: protocol for a two-centre, randomised, double-blind, placebo-controlled trial, The 'UP' study
por: Payne, Thomas, et al.
Publicado: (2020)

A study protocol for a phase II randomised, double-blind, placebo-controlled trial of sodium selenate as a disease-modifying treatment for behavioural variant frontotemporal dementia
por: Vivash, Lucy, et al.
Publicado: (2020)

Use of Fast Gamma Magnetic Stimulation Over the Left Prefrontal Dorsolateral Cortex for the Treatment of MCI and Mild Alzheimer's Disease: A Double-Blind, Randomized, Sham-Controlled, Pilot Study
por: Mimenza-Alvarado, Alberto José, et al.
Publicado: (2021)

Recognizing the role of the vagus nerve in depression from microbiota-gut brain axis
por: Tan, Chaoren, et al.
Publicado: (2022)

The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson’s disease
por: Li, Qing, et al.
Publicado: (2023)

Repurposing bromocriptine for Aβ metabolism in Alzheimer’s disease (REBRAnD) study: randomised placebo-controlled double-blind comparative trial and open-label extension trial to investigate the safety and efficacy of bromocriptine in Alzheimer’s disease with presenilin 1 (PSEN1) mutations
por: Kondo, Takayuki, et al.
Publicado: (2021)

Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study
por: Polymeropoulos, Vasilios M., et al.
Publicado: (2020)

Effects of Unilateral Stimulation in Parkinson's Disease: A Randomized Double-Blind Crossover Trial
por: Zeng, Zhitong, et al.
Publicado: (2022)

Safety and Tolerability, Dose-Escalating, Double-Blind Trial of Oral Mannitol in Parkinson's Disease
por: Linetsky, Eduard, et al.
Publicado: (2022)

Givinostat for Becker muscular dystrophy: A randomized, placebo-controlled, double-blind study
por: Comi, Giacomo P., et al.
Publicado: (2023)

Gut Microbiota Dysbiosis in Acute Ischemic Stroke Associated With 3-Month Unfavorable Outcome
por: Sun, Huanhuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4rmq2lg5cnvt9m8ffgr6i4vldo